Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention

In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome. However, these RCTs indicated a higher bleeding risk with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Arun, Lutsey, Pamela L., St. Peter, Wendy L., Schommer, Jon C., Van't Hof, Jeremy R., Rajpurohit, Abhijeet, Farley, Joel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107606/
https://www.ncbi.nlm.nih.gov/pubmed/36448257
http://dx.doi.org/10.1002/cpt.2806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107606/
https://www.ncbi.nlm.nih.gov/pubmed/36448257
http://dx.doi.org/10.1002/cpt.2806

Ejemplares similares